B1, native coronary artery lesion treatment. 2. Target lesion must be located in a native vessel with a diameter of 3.0 mm assessed by QCA on-line. 3. Target lesion length ≤ 12 mm, assessed by QCA on-line. 4. The target lesion must be in a major artery or branch with a stenosis of ≥ 50% and < 100% assessed by QCA on-line and with a TIMI flow of ≥ 1. Exclusion Criteria 1. Patient has had a known acute myocardial infarction (greater than two times the upper limit of normal CK with presence of CK-MB) within 3 days preceding the index procedure and CK has not returned to normal limits at the time of the procedure. 2. Patient has current or a history of unstable arrhythmias, regardless of whether cardiac rhythm management devices are used (e.g., pacemaker, Automatic Implantable Cardioverter Defibrillator). 3. Patient has a known left ventricular ejection fraction ≥ 30%. 4. Patient has received a heart transplant or any other organ transplant or is on a waiting list for any organ transplant. 5. Patient is receiving or scheduled to receive chemotherapy or radiation therapy within 30 days prior to or after the procedure. 6. Patient is receiving immunosuppression therapy or has known immunosuppressive disease. 7. Patient is receiving chronic anticoagulation therapy (e.g., heparin, coumadin). 8. Patient has a known hypersensitivity or contraindication to aspirin, heparin, clopidogrel, cobalt, chromium, nickel, tungsten, everolimus, acrylic and fluoro polymers or contrast sensitivity that cannot be adequately pre-medicated. 9. Patient has a platelet count <100,000 cells/mm3 or >700,000 cells/mm3, a WBC of <3,000 cells/mm3, or documented or suspected liver disease (including laboratory evidence of hepatitis). 10. Patient has known renal insufficiency (e.g., serum creatinine level of more than 2.5 mg/dL, patient on dialysis). 11. Patient has a history of bleeding diathesis or coagulopathy or will refuse blood transfusions. 12. Patient has had a cerebrovascular accident (CVA) or stroke or transient ischemic neurological attack (TIA) within the past six months. 13. Patient has had a significant GI or urinary bleed within the past six months. 14. Patient has extensive peripheral vascular disease that precludes safe 6 French sheath insertion or extreme anticoagulation. 15. Patient has other medical illness (e.g., cancer or congestive heart failure) or recent history of substance abuse that may cause non-compliance with the protocol, confound the data interpretation or is associated with a limited life expectancy (i.e., less than one year). 16. Patient is already participating in another investigational use device or drug study or has completed the follow-up phase of another trial within the last 30 days. 17. Patient has received a drug eluting stent within the last 1 year. [clinicaltrials_resource:10ca8a81ce1f88bc9f74d406248a7f40]